Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 474

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 19
Chunk 474
---
 December 31, 2022 included a discount rate of 12.5%, an appropriate probability of success of reaching these milestones and expected timing of these milestones, in line with the timelines and probabilities used in our impairment test of the CAR-T business. As per December 31, 2024 changes were made to the discount rate (13.75% at December 31, 2024 and 13.72% at December 31, 2023) and the expected timing of the milestones. The only impact that was recognized compared to the date of acquisition is the discounting effect. This is recognized on the line “other financial income”. A change in probabilities of success by 5 percentage points would result in a change of €2.9 million in the total contingent consideration liability on December 31, 2024. A change in the applied discount rate by  percentage point would result in a change of €0.6 million in the total contingent consideration liability on December 31, 2024. A delay of one year in expected timing of the milestones would result in a decrease of €2.5 million in the total contingent consideration liability on December 31, 2024. 
​

F-53

27. Deferred incomeThe movement in the non-current and current deferred income is detailed in the table below.​

                                                      ​                                                         ​       ​            ​        ​        ​             ​        ​      ​         ​      ​   ​        ​    
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
​                                                                                                                   Gilead collaboration          Gilead collaboration            Other                   Total         
                                                                                                                    agreement                     agreement                       deferred income                       
                                                                                                                    for filgotinib                for drug                                                              
                                                                                                                                                  discovery platform (1)                                                
​                                                                                                               ​   (Euro, in thousands)                                                                                
​                                                                                                               ​   ​            ​            ​   ​             ​             ​   ​         ​             ​            ​
On January 1, 2023                                                                                              ​   €            456,352      ​   €             1,529,405     ​   €         3,474     ​   ​    1,989,230
Of which current portion:                                                                                       ​   ​            133,470      ​   ​             230,022       ​   ​         2,139     ​   ​      365,631
​                                                                                                               ​   ​            ​            ​   ​             ​             ​   ​         ​         ​   ​            ​
Reclassification to liabilities directly